Atalanta Therapeutics raises $97 million in Series B funding to accelerate RNA interference therapies into Phase 1 trials, …
Atalanta Therapeutics raises $97 million in Series B funding to accelerate RNA interference therapies into Phase 1 trials, …
Despite a cautious capital environment, North American biotech companies secured nearly $2 billion in funding in January 2025, with …
A three-year collaboration between Vertex and Orna Therapeutics brings cutting-edge lipid nanoparticle delivery into the spotlight, aiming to …
Shanghai-based Excalipoint secures rights to two preclinical T-cell engagers from Lepu Biopharma, aiming to fast-track development for solid …
Landmark Series A round positions Australian biotech at the forefront of neurodegenerative disease innovation.
The CGM giant and smart ring innovator join forces to integrate biosensor data and reshape personal health tracking.
Leading biopharma firms are harnessing AI-driven collaborations to accelerate drug discovery and deliver transformative healthcare solutions.
With a blockbuster IPO on the horizon, Australian biotech innovation is drawing global eyes and fresh capital to …
AI-driven drug discovery is accelerating innovation and transforming biopharma R&D.
Australia’s National Genomic Registry is connecting patients, clinicians, and researchers to transform rare disease care in real time.
Already a subscriber? Log in